Earnings summaries and quarterly performance for Shuttle Pharmaceuticals Holdings.
Executive leadership at Shuttle Pharmaceuticals Holdings.
Board of directors at Shuttle Pharmaceuticals Holdings.
Research analysts covering Shuttle Pharmaceuticals Holdings.
Recent press releases and 8-K filings for SHPH.
Shuttle Pharmaceuticals Holdings, Inc. Enters into Asset Purchase Agreement
SHPH
M&A
New Projects/Investments
- Shuttle Pharmaceuticals Holdings, Inc. (SHPH), through its wholly-owned subsidiary, entered into an Asset Purchase Agreement on November 20, 2025, to acquire substantially all assets and liabilities of 1542770 BC Ltd..
- The aggregate consideration for the acquisition includes an initial $3,000,000 cash payment made on the closing date, with additional fixed installment contributions of $3,000,000 payable on the 6-month anniversary and $2,000,000 payable on the one-year anniversary of the Closing Date.
- The agreement also provides for potential contingent payments of $1,000,000 each upon the achievement of two milestones: the extension of the Seller's current AI model to support drug-target interaction by the 3-month anniversary, and the production of a first version of Agentic AI mode for automatic drug discovery by the 6-month anniversary of the Closing Date.
- All consideration beyond the initial cash payment may be paid in cash, shares of Company Common Stock, or a combination thereof, at the Seller's discretion, provided that the total number of shares of Company Common Stock issued will not exceed 19.99% of the issued and outstanding shares as of the Closing Date without stockholder approval.
Nov 26, 2025, 5:28 PM
Shuttle Pharmaceuticals Holdings, Inc. Announces Securities Offering
SHPH
New Projects/Investments
- On November 3, 2025, Shuttle Pharmaceuticals Holdings, Inc. entered into a Securities Purchase Agreement to issue and sell securities.
- The company will raise approximately $2,500,624 through an offering of common stock and pre-funded warrants.
- The pre-funded warrants allow for the purchase of up to 625,156 shares of common stock, with an issue and initial exercise date of November 4, 2025.
- The net proceeds from the sale will be used for general corporate purposes, working capital, and up to $800,000 for marketing.
- The company plans to file a Registration Statement covering the sale of these shares and pre-funded warrant shares within 15 days of November 3, 2025.
Nov 7, 2025, 9:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more